U.S. Other Utilities Stock News

NYSE:HAE
NYSE:HAEMedical Equipment

Assessing Haemonetics (HAE) Valuation After FDA Clearance Of NexSys PCS Persona PLUS System

Haemonetics (HAE) is back in focus after receiving FDA 510(k) clearance for its NexSys PCS Plasma Collection System with Persona PLUS, a next-generation platform designed to tailor plasma collection volumes to individual donors. See our latest analysis for Haemonetics. Despite the FDA clearance and recent conference appearance, Haemonetics’ share price, last closing at $63.88, shows mixed momentum. The stock has a 4.23% 7 day share price return, but a 20.13% decline year to date and a 20.93%...
NYSE:MTDR
NYSE:MTDROil and Gas

Is It Too Late To Consider Matador Resources (MTDR) After Its Recent Share Price Surge

If you are wondering whether Matador Resources at around US$54.12 is priced attractively or already baking in a lot of optimism, you are not alone. The stock has returned 5.8% over the last 7 days, 19.6% over the last 30 days, 24.8% year to date, 16.9% over 1 year, 0.7% over 3 years and 131.2% over 5 years, which naturally raises questions about what is already reflected in the price. Recent attention on Matador Resources has focused on its position in the US energy sector and how investors...
NasdaqGS:FTDR
NasdaqGS:FTDRConsumer Services

Is It Too Late To Consider Frontdoor (FTDR) After Its Strong Multi Year Share Price Rally

If you are wondering whether Frontdoor's share price still reflects good value after a strong run, this article walks through what the current market price might be implying about the business. Frontdoor's stock closed at US$67.46, with returns of 22.7% over the last 7 days, 14.1% over 30 days, 18.3% year to date, 65.9% over 1 year and 135.1% over 3 years, while the 5 year return sits at 24.2%. Recent coverage has focused on Frontdoor's position in home service plans and how its offerings...
NYSE:GS
NYSE:GSCapital Markets

Lloyd Blankfein Flags Shadow Banking Risks For Goldman Sachs Investors

Former Goldman Sachs (NYSE:GS) CEO Lloyd Blankfein has warned of potential systemic risks tied to the rapid expansion of private credit and shadow banking. His comments focus on hidden leverage and illiquid assets that may sit outside traditional bank balance sheets. The warning comes as investors pay closer attention to how credit risk is distributed across banks, non bank lenders, and the broader financial system. Goldman Sachs is a global investment bank and financial services firm...
NYSE:PSTG
NYSE:PSTGTech

Assessing Everpure (PSTG) Valuation After Strong Results Guidance And Share Buybacks

Why Everpure’s latest earnings matter for shareholders Everpure (PSTG) has drawn fresh attention after reporting fourth quarter and full year results alongside new revenue guidance and an update on its share repurchase activity, giving investors several moving pieces to assess. For the fourth quarter ended February 1, 2026, the company reported revenue of US$1,058.9 million, compared with US$879.84 million a year earlier. Net income for the period was US$100.25 million versus US$42.44 million...
NYSE:TEVA
NYSE:TEVAPharmaceuticals

Teva Drug Updates Support Branded Growth Story And Valuation Upside Potential

Teva Pharmaceutical Industries (NYSE:TEVA) received FDA acceptance of its New Drug Application for an extended-release injectable formulation of olanzapine for schizophrenia treatment. The company also reported strong long-term clinical trial results for duvakitug in ulcerative colitis and Crohn’s disease, developed in partnership with Sanofi. Both updates add fresh momentum to Teva’s branded pipeline alongside its established generics business. For investors watching Teva’s shift toward...
NYSE:ALK
NYSE:ALKAirlines

Is Alaska Air Group (ALK) Pricing Reflect Recent Airline Sector Risks Accurately

If you are wondering whether Alaska Air Group is attractively priced at its current level, looking closely at how its valuation stacks up against its fundamentals can help frame that decision. The stock last closed at US$50.77, with returns of 0.3% over the past 7 days, a 0.1% decline over 30 days, a 1.5% decline year to date, a 27.4% decline over 1 year, a 6.0% gain over 3 years and a 25.3% decline over 5 years, which gives you a mixed picture of recent and longer term performance. Recent...
NYSE:NVO
NYSE:NVOPharmaceuticals

Assessing Novo Nordisk (NYSE:NVO) Valuation After Recent Share Price Weakness

Event-driven snapshot of Novo Nordisk (NYSE:NVO) Novo Nordisk (NYSE:NVO) has drawn investor attention after its recent share performance, with the stock showing a 0.8% move over the past day and declines over the past week, month, and past 3 months. See our latest analysis for Novo Nordisk. That 0.8% 1 day share price gain comes after a sharp 36.5% 30 day share price decline and a 27.9% year to date share price fall, while the 1 year total shareholder return of 56.9% and 3 year total...
NasdaqGS:PLTR
NasdaqGS:PLTRSoftware

Palantir Deepens U.S. Defense Role As AI Platform Adoption Widens

Palantir Technologies (NasdaqGS:PLTR) is reported to play a critical role in U.S. defense planning and data analysis tied to the Middle East conflict and Operation Epic Fury. The U.S. Department of Defense has increased its reliance on Palantir after blacklisting Anthropic, concentrating more national security AI work with the company. New multi year contracts with the Department of Homeland Security and broader adoption of Palantir's AI platform across government and commercial users point...
NYSE:SOC
NYSE:SOCOil and Gas

Assessing Sable Offshore (SOC) Valuation After Fund Inflows Losses And Las Flores Legal Uncertainty

Sable Offshore (SOC) is back on investor radar after FourWorld Capital Management took a large new stake, just as the company reported a US$410.2 million full year 2025 net loss tied to restart related costs. See our latest analysis for Sable Offshore. The share price has been volatile, with a 90 day share price return of 90.69% from a low base. However, the 1 year total shareholder return of 67.06% and year to date share price return of 26.68% indicate that longer term momentum has faded. If...
NasdaqGS:RELY
NasdaqGS:RELYDiversified Financial

A Look At Remitly Global (RELY) Valuation After CEO Transition And Return To Profitability

Why Remitly’s leadership shift and profit milestone matter for shareholders Remitly Global (RELY) has drawn fresh attention after appointing Sebastian J. Gunningham as CEO, while co founder Matt Oppenheimer becomes Chairman, alongside earnings that show a return to profitability and new guidance for 2026. See our latest analysis for Remitly Global. The recent CEO transition and profit update come as Remitly’s share price, now at $16.93, has logged a 30 day share price return of 28.06% and a...
NYSE:MDT
NYSE:MDTMedical Equipment

Medtronic’s MiniMed Go Launch Tests Diabetes Growth Hopes And Valuation

Medtronic (NYSE:MDT) has launched its MiniMed Go Smart MDI system with the integrated Simplera sensor across Europe. The system connects smart insulin pen and sensor data into a single mobile app aimed at people using multiple daily injections for diabetes management. This marks a fresh product rollout for Medtronic's diabetes portfolio that has not featured in recent company news coverage. For investors watching Medtronic at a share price of $98.1, this launch adds a new element to the...
NYSE:AZO
NYSE:AZOSpecialty Retail

Is AutoZone (AZO) Still Attractively Priced After A Strong Multi‑Year Share Price Run?

If you are wondering whether AutoZone's share price still reflects good value after a long run in the auto parts sector, this article will help you break that question into clear valuation checks. AutoZone shares most recently closed at US$3,882.47, with returns of 1.4% over 7 days, 4.8% over 30 days, 17.5% year to date, 11.6% over 1 year, 54.1% over 3 years and 212.8% over 5 years. This gives plenty of history for investors to consider. Recent news coverage around AutoZone has focused on...
NasdaqGS:ARHS
NasdaqGS:ARHSSpecialty Retail

Arhaus (ARHS) Valuation Check After Recent Share Price Pullback

Why Arhaus Stock Is Drawing Attention Now Arhaus (ARHS) has pulled back recently, with the share price down over the past month and past 3 months. This move is prompting investors to reassess how its current valuation lines up with the underlying business. The company reports annual revenue of US$1,379.2m and net income of US$67.3m, and some models suggest the shares trade at a sizeable discount to certain intrinsic value estimates. This can attract interest from value oriented investors. See...
NasdaqCM:NNE
NasdaqCM:NNEElectrical

Does NANO Nuclear Energy (NNE)ʼs Gulf MMR Venture Hint at a Scalable Global Deployment Strategy?

NANO Nuclear Energy Inc. recently signed a Memorandum of Understanding with Abu Dhabi–based EHC Investment L.L.C. to explore a joint venture for deploying its KRONOS MMR™ Energy System and associated supply chains in the UAE and potentially across the wider Gulf region. The agreement underscores growing interest in micro modular reactors as a carbon free power option for energy intensive infrastructure such as data centers and industrial facilities, while NANO Nuclear and EHC assess...
NYSE:SPG
NYSE:SPGRetail REITs

A Look At Simon Property Group (SPG) Valuation As Shares Trade Near Analyst Targets

Simon Property Group (SPG) has drawn fresh attention after its recent share performance, with the stock closing at $203.16 and posting gains over the past week, month, past 3 months and year. See our latest analysis for Simon Property Group. While the share price slipped 0.34% on the day to US$203.16, the 30 day share price return of 6.19% and year to date gain of 10.43% suggest momentum has been building, supported by a 1 year total shareholder return of 13.68% and very strong 3 and 5 year...
NYSE:LYV
NYSE:LYVEntertainment

A Look At Live Nation (LYV) Valuation As DOJ Antitrust Trial Targets Ticketmaster’s Market Power

The Justice Department’s trial seeking to break up Live Nation Entertainment (LYV) and Ticketmaster puts antitrust risk at the center of the story, as investors weigh potential changes to the company’s structure and ticketing power. See our latest analysis for Live Nation Entertainment. The share price, now at US$161.81, has had an 11.25% 30 day share price return and a 25.88% 90 day share price return. The 3 year total shareholder return of 122.88% sets the backdrop for how investors are...
NYSE:LNG
NYSE:LNGOil and Gas

Why Cheniere Energy (LNG) Is Up 11.5% After Key DOE Approval For Corpus Christi Expansion

The U.S. Department of Energy has approved a 12% expansion of Cheniere Energy’s Corpus Christi LNG terminal, authorizing additional exports from Trains 8 and 9 to non‑free‑trade‑agreement countries and raising total export capacity to 4.45 billion cubic feet per day. This regulatory green light materially enlarges Cheniere’s permitted export footprint, reinforcing its role as a major U.S. LNG supplier to global markets. Next, we’ll examine how this export expansion approval at Corpus Christi...
NasdaqGS:OKTA
NasdaqGS:OKTAIT

Okta’s AI Identity Push And PGA Deal Set Against Weak Stock Returns

Okta (NasdaqGS:OKTA) has launched new AI-focused security tools, including Auth0 for AI Agents, aimed at managing identity for autonomous systems. The company also expanded its partnership with the PGA of America to strengthen identity security for golf professionals and fans. These moves highlight Okta's focus on AI-driven identity security and its push to extend its reach with high profile enterprise partners. Okta's latest product launches arrive at a time when the stock trades around...
NasdaqGS:GILT
NasdaqGS:GILTCommunications

Why Gilat Satellite Networks (GILT) Is Up 20.6% After New 5G GEO Breakthrough And Defense Wins

In late February 2026, Gilat Satellite Networks announced successful 3GPP-compliant 5G Non-Terrestrial Network connectivity over a GEO satellite, alongside US$39,000,000 of new orders for its Sidewinder in-flight connectivity terminals and a US$9,000,000 satellite communications contract from Israel's Ministry of Defense. Together, these wins highlight Gilat's strengthening role in next-generation satellite communications across commercial aviation, defense, and integrated 5G...
NYSE:BE
NYSE:BEElectrical

Will Bloom Energy's (BE) Q4 Beat and Data Center Backlog Shift Its Hydrogen Power Narrative?

In late February 2026, Bloom Energy reported fourth-quarter 2025 results that exceeded analyst expectations, with earnings per share of US$0.45 and revenue about 21.5% above forecasts, alongside strong backlog growth from data center and commercial customers. This performance, set against growing interest in solid oxide electrolyzer technology and policy support for low-carbon hydrogen, highlighted how Bloom’s positioning at the intersection of hydrogen and on-site power is becoming...
NYSE:HIG
NYSE:HIGInsurance

Is Hartford (HIG) Still Attractive After A 20% One Year Share Price Gain?

If you are wondering whether Hartford Insurance Group shares still offer value after a strong run, it helps to step back and look at what the current price is really implying. The stock last closed at US$141.86, with returns of 0.9% over 7 days, 5.0% over 30 days, 3.5% year to date, 20.4% over 1 year, 93.2% over 3 years and 186.4% over 5 years. This naturally raises questions about how much of the story is already priced in. Recent news around Hartford has focused on its position within the...
NYSE:G
NYSE:GProfessional Services

Assessing Genpact (G) Valuation After Strong Q3 2025 AI-Led Results And Upgraded Guidance

Q3 2025 results spotlight AI-first pivot Genpact (G) recently reported strong Q3 2025 results, putting its AI-focused shift and agentic operations in the spotlight and giving investors fresh data on how platforms like AI Maestro and key cloud partnerships are translating into business momentum. See our latest analysis for Genpact. The Q3 update comes after a mixed period for investors, with the share price at US$40.21 and a recent 7 day share price return of 7.11% contrasting with a weaker...
NasdaqGM:AXSM
NasdaqGM:AXSMPharmaceuticals

Should Axsome’s Revenue Jump and SUNOSI IP Win Require Action From Axsome Therapeutics (AXSM) Investors?

In late February 2026, Axsome Therapeutics reported fourth-quarter 2025 revenue of US$196 million and full-year revenue of US$638.5 million, with net losses narrowing year over year, while also settling SUNOSI patent litigation with Alkem and dosing the first patient in its Phase 3 CLARITY trial of solriamfetol in major depressive disorder with excessive daytime sleepiness. Taken together with upcoming healthcare conference presentations, these updates underscore Axsome’s efforts to both...